Toggle light / dark theme

Vaccines have advanced the field of health and medicine throughout the last century. They are commonly given before a disease can occur to expose individuals to invading pathogens. Vaccines given as a preventative treatment helps the immune system build an immune response against disease that the person may encounter in the future. When an individual gets a shot at the doctor’s office they are injecting an attenuated version of the disease. The body will then recognize this pathogen as foreign and build an immune response against it. This is why many times a person feels sick after a few days from a vaccination – the body is activating the immune system to eliminate the disease.

Many types of vaccines exist and are developed to optimize delivery of attenuated pathogen. Arguably, the most well-known type of vaccine uses messenger ribonucleic acid (mRNA). These vaccines work by delivering mRNA of a virus, which allows human cells to produce viral protein. The immune system responds strongly to the viral proteins and targets them with different immune cells, while also generating antibodies against it. Once the body has built this response, the immune system can more easily target the same virus in the future. This recognition of specific infections is referred to as immunological memory. Currently, the only mRNA vaccines Food and Drug Administration (FDA) approved are for COVID-19. However, the efficient use of mRNA vaccines for COVID-19 have scientists wondering if this format can be used in other disease settings, including cancer.

A recent article in Nature Communications, by Dr. Damya Laoui and others introduce a novel therapeutic approach in which mRNA is integrated into nanoparticles to overcome tumor progression. Laoui is a group leader at Vlaams Instituut voor Biotechnologie (VIB) in Brussels, Belgium. Her work focuses on immune cell activation through specific immune cells known as macrophages and dendritic cells. Laoui also works on developing novel personalized immunotherapies for patients with hard-to-treat cancers.

Researchers think certain common viruses may trigger some autoimmune conditions—alone or in concert with other factors. A recent Office of Autoimmune Disease Research (OADR)-Office of Research on Women’s Health Science Talks series focused on understanding the triggers of autoimmunity and advancing research.

Almost 80 percent of people living with an autoimmune disease are women. It’s estimated there are 80–120 autoimmune diseases. These chronic and often debilitating diseases have no known cures. Some combination of genetics, immune regulation and the environment work together to form an “endotype” for each autoimmune disease patient, explained Dr. Judith James of the Oklahoma Medical Research Foundation.

Her presentation focused on lupus, or systemic lupus erythematosus (SLE), which disproportionately affects women. Nine women are diagnosed with SLE for every male. In SLE, the immune system attacks healthy tissue, causing inflammation and occasionally permanent damage.

Saar Yoskovitz is Co-Founder & CEO at Augury, a pioneer in AI-driven Machine Health and Process Health solutions for industrial sectors.

American manufacturers are at a crossroads, needing to decide between evolution and obsolescence. The tools that historically drove profitability and efficiency are no longer having an impact. Labor is hard to find and harder to keep. The National Association of Manufacturing projects that 2.1 million manufacturing roles will go unfilled by 2030. This hard truth is compounded by findings in Augury’s State of Production Health report, which reveals that 91% of manufacturers say that the mass exodus of industry veterans will worsen the knowledge gap.

An alarming rate of brain drain is looming over the industrial sector. As tenured employees reach retirement age and fewer professionals line up to take their place, more manufacturers are turning to artificial intelligence (AI) to bridge the gap.

Cells in the immune system don’t always fight; they often rest and wait for threats, like viruses or bacteria. When such threats emerge, the cells activate to defend the body. This delicate balance between rest and activation is crucial to our health—immune cells must be poised for activation to protect against threats, but if they’re overly active, autoimmune diseases can result.

But what controls this important balance?

In a new study published in Nature, scientists from Gladstone Institutes and UC San Francisco (UCSF) focused on T cells—which serve a vital role in the immune system—and pinpointed how a network of different proteins controls rest and activation.

Human fingerprints are detailed, unique, difficult to alter, and durable over the life of an individual, making them suitable as long-term markers of human identity. Could the same concept be used to help identify cancer? A new study by researchers at the Centre for Genomic Regulation (CRG) in Barcelona reveals different types of cancer have unique molecular “fingerprints” that are detectable in the early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in a few hours. The discovery lays the groundwork for creating new, noninvasive diagnostic tests that detect different types of cancer faster and earlier than currently possible.

The findings are published in the journal Molecular Cell in an article entitled “Epitranscriptomic rRNA fingerprinting reveals tissue-of-origin and tumor-specific signatures.”

“Our ribosomes are not all the same. They are specialized in different tissues and carry unique signatures that reflect what’s happening inside our bodies,” explained ICREA research professor Eva Novoa, PhD, lead author of the study and researcher at the CRG. “These subtle differences can tell us a lot about health and disease.”

Researchers have developed a device that can simultaneously measure six markers of brain health. The sensor, which is inserted through the skull into the brain, can pull off this feat thanks to an artificial intelligence (AI) system that pieces apart the six signals in real time.

Being able to continuously monitor biomarkers in patients with traumatic brain injury could improve outcomes by catching swelling or bleeding early enough for doctors to intervene. But most existing devices measure just one marker at a time. They also tend to be made with metal, so they can’t easily be used in combination with magnetic resonance imaging.


Simultaneous access to measurements could improve outcomes for brain injuries.

A research team from the Nagoya University Graduate School of Medicine has discovered a promising way to slow the progression of heart failure in mice. They fed mice a diet rich in the soybean protein, β-conglycinin (β-CG), which can support heart health by influencing gut bacteria. Their analysis revealed that the soybean protein rich diet increased the production of the short-chain fatty acids (SCFAs) in the intestine that play a role in protecting the heart. Their findings were published in Clinical Nutrition.

Many people with heart problems try to eat a nutritious diet to reduce their risk of disease. As part of a healthy diet, soybeans have long been recognized for their antioxidant and anti-inflammatory properties. Based on this, the researchers suspected that proteins in soy may help prevent heart damage.

Dr. Nozomi Furukawa and colleagues fed the soy-derived protein β-CG to mice prone to heart failure and investigated its effects on the heart. The mice showed improved heart function, less muscle thickening, and reduced scarring of the heart tissue, common problems associated with the progression of heart disease.

Ultimately, the goal is to find ways to stop deadly disease caused by Cryptococcus neoformans from developing in humans and animals. But until that time, finding new and better ways to treat already existent disease and its symptoms is a high priority.

The laboratory of Kirsten Nielsen in the Center for One Health Research has taken a step toward improved treatment of Cryptococcus, completing a six-year study to examine the virulence of 38 clinical isolates from various strains of Cryptococcus. The results are published in Nature Communications.

“The question that we’ve been addressing is: Can we predict severe disease outcomes in patients?” said Nielsen, professor of microbiology and immunology in the Virginia-Maryland College of Veterinary Medicine. “If we can predict disease outcome, then we can treat patients better. In these studies, we identified not just the genes that allow Cryptococcus to cause disease, but also the gene alleles that allow it to cause more disease or less disease.”

Delivering Innovative, Compassionate And Accessible Patient Care — Robert Stone, CEO — City of Hope & Dr. Marcel van den Brink, MD, PhD, President, City of Hope Comprehensive Cancer Center.


Robert Stone is the CEO of City of Hope (https://www.cityofhope.org/robert-stone), a premier cancer research and treatment center dedicated to innovation in biomedical science and the delivery of compassionate, world-class patient care. A seasoned health care executive, he has served in a number of strategic decision-making roles since he joined City of Hope in 1996, culminating with his appointment as president in 2012, CEO in 2014, and as the Helen and Morgan Chu Chief Executive Officer Distinguished Chair in 2021.

Mr. Stone has J.D., University of Chicago Law School, Chicago, IL.

Mr. Stone’s strategic acumen, empathy and visionary leadership have driven City of Hope’s rapid evolution.

As an independent institution dedicated to advancing the fight against cancer and diabetes, City of Hope is accelerating opportunities for high-impact discovery and ensuring that patients around the world have access to the most advanced therapies. Recent examples include a groundbreaking alliance in precision medicine with the Translational Genomics Research Institute (TGen), a leader in genomic analysis and bioinformatics; leadership in CAR T cell therapy research and therapy; and an innovative program to offer cancer support services to the employees of some of American’s largest employers, regardless of geography.

A new UC Davis Health study has uncovered how Salmonella bacteria, a major cause of food poisoning, can invade the gut even when protective bacteria are present. The research, published in the Proceedings of the National Academy of Sciences, explains how the pathogen tricks the gut environment to escape the body’s natural defenses.

The digestive system is home to trillions of bacteria, many of which produce short-chain fatty acids (SCFAs) that help fight harmful pathogens. But Salmonella manages to grow and spread in the gut, even though these protective compounds are present. The study asks: How does Salmonella get around this defense?

“We knew that Salmonella invades the small intestine, although it is not its primary site of replication. The colon is,” said the lead author of the study Andreas Bäumler is a UC Davis distinguished professor and vice chair of research in the Department of Medical Microbiology and Immunology.